Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer
Titel:
Cost-effectiveness analysis of VEGF-A testing to predict response to bevacizumab (BEV) as a component of neo-adjuvant therapy of early HER-2 negative breast cancer
Auteur:
Blank, P.R. Loibl, S. Linderholm, B.K. Caramuta, S. Nekljudova, V. Szucs, T.D. Van Stiphout, J. Ademi, Z. von Minckwitz, G. Schwenkglenks, M.